Forest Laboratories Receives Notification of ANDA Filings for Generic Equivalents of Namenda(R)
December 13 2007 - 4:20PM
PR Newswire (US)
NEW YORK, Dec. 13 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE:FRX), announced today that it has received notification
from several companies that they have filed Abbreviated New Drug
Applications (ANDA) with Paragraph IV Certifications to obtain
approval to market generic equivalents of Namenda, an NMDA receptor
antagonist indicated for the treatment of moderate to severe
dementia of the Alzheimer's type. The Company intends to pursue all
appropriate legal action to defend its intellectual property
related to Namenda. Namenda is covered by an issued U.S. patent
which is set to expire in April 2010. Forest has applied for patent
term restoration which, if granted, would extend Namenda's patent
protection until September 2013. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) Except
for the historical information contained herein, this release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform act of 1995. These statements
involve a number of risks and uncertainties, including the
difficulty of predicting FDA approvals, the acceptance and demand
for new pharmaceutical products, the impact of competitive products
and pricing, the timely development and launch of new products, and
the risk factors listed from time to time in each of Forest
Laboratories' Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q, and any subsequent SEC filings.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
http://photoarchive.ap.org/ DATASOURCE: Forest Laboratories, Inc.
CONTACT: Charles E. Triano, Vice President - Investor Relations of
Forest Laboratories, Inc., +1-212-224-6714, Web site:
http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024